Vilon Peptide (KE): Bioregulator for Immune Aging and Epigenetics

How a two-amino-acid sequence rewires aging immune cells at the chromatin level

Vilon is a synthetic dipeptide bioregulator with two amino acids. Its primary research area is not any single measurable output but the underlying regulatory machinery governing how aging immune cells express their genes. For researchers familiar with Epitalon or the Khavinson bioregulator framework, Vilon fills a specific gap: thymus-targeted epigenetic modulation in the context of immunosenescence.

What Is Vilon (KE)?

Vilon is the research name for the synthetic dipeptide Lys-Glu, also written as L-lysyl-L-glutamic acid, lysylglutamate, or Lysylglutamic acid. Alternative names in the literature include KE peptide and Normophthal. It was originally isolated from thymus tissue extracts, then synthesized as a defined chemical entity within the Khavinson bioregulator class, which also includes Epitalon (pineal) and Cardiogen (cardiac).



Unlike peptides that operate through receptor binding or direct hormonal signaling, Vilon's mechanism is primarily epigenetic and immune-regulatory. It does not stimulate growth hormone, modulate appetite signaling, or act through the BPC-157 or TB-500 tissue-repair pathways.

How Vilon Works: Chromatin, NF-kB, and Immune Reprogramming

In aging cells, regions of the genome that were once transcriptionally active become condensed into heterochromatin, a tightly packed form that silences gene expression. Vilon has been shown in cell and tissue models to promote deheterochromatinization: the loosening of condensed chromatin back toward transcriptionally active euchromatin [1, 2].

In lymphocytes from elderly donors, Vilon reactivates nucleolar organizer regions responsible for ribosomal RNA synthesis and restores protein production capacity that had declined with age [3]. In aging human mesenchymal stem cell models, it normalizes telomere dynamics and modulates expression of genes including IGF1, FOXO1, TERT, TNKS2, and NF-kB pathway components [4].

At the immune cell level, in vitro work shows Vilon upregulates surface markers including CD4, CD5, HLA-DR, and CD54, supporting T-helper differentiation and improved blast-transformation responses in aged cell models [5]. It also alters MMP-9 expression and increases Ki-67 in fibroblast cultures, suggesting broader effects on proliferative repair capacity [6].

Vilon Research: Key Findings

The primary research base originates in Russian clinical and preclinical work, with follow-on investigation in international cell biology and epigenetics literature.

Immunocorrection and aging. Early work with the thymic extract Thymalin identified the active dipeptide KE as a key mediator of immune normalization in older and immunocompromised subjects, showing improvements in cellular immunity, macrophage activity, and nonspecific resistance [7]. Vilon as a defined compound produced more consistent results than complex extracts, allowing for cleaner mechanistic investigation.

Oncology-adjacent research. In transgenic mouse models, KE-class peptides reduced expression of certain oncogenes including HER-2/neu and modulated tumor-related gene expression, generating interest as a potential adjuvant rather than standalone treatment [8].

Most structured data come from disease and elderly cohorts rather than healthy younger populations, an important caveat for biohacking extrapolation.



Potential Benefits (Research Only)

• Immune aging: T-helper differentiation, normalized blast-transformation, improved surface marker profiles in aged cell models [5].
• Inflammaging: NF-kB pathway modulation and reduced pro-inflammatory cytokine synthesis in stimulated immune cell models [4].
• Epigenetic dynamics: Influence on TERT, FOXO1, and chromatin architecture connects Vilon to longevity signaling pathways [4].
• Tissue and organ support: MMP-9 and Ki-67 changes in fibroblast cultures; research into cardiovascular and renal contexts remains early-stage [6].

Protocols in the Literature

The following describes parameters from research literature only. This is not dosing guidance. All use should occur under qualified clinical oversight. See the peptide calculator for reconstitution reference.

• Immune and longevity focus: 10 mg SC once daily for 5 to 10 days, repeated every 3 to 6 months.
• Anti-aging emphasis: 10 mg SC daily for 10 days, twice per year.
• Pulsed micro-dose variants: sub-milligram amounts scaled to 0.3 to 0.7 mg daily over 5-day cycles with approximately 3-week off-phases.

Long-term safety data in healthy biohacking populations are sparse. Most structured clinical data involve elderly or disease-affected cohorts [7].

How Vilon Compares to Epitalon

Vilon targets the thymus and immune system via chromatin remodeling. Epitalon targets the pineal gland through telomerase activation and circadian pathway effects. They operate on different organ axes and are frequently combined for complementary coverage. For the full Epitalon protocol including dosing, cycling, and stacking strategies, see our Epithalon biohacking guide.

Sourcing Vilon Responsibly

Vilon is available as a lyophilized research compound, typically in 20 mg vials at stated purity of 99 percent or higher, labeled as Lys-Glu, Lysylglutamate, or KE peptide. The peptide vendor directory lists vendors reviewed for COA documentation standards.

Evaluate sourcing based on HPLC or LC-MS methodology, batch-specific COA results, and explicit compound identification. For what third-party testing documentation should actually contain, see third-party testing: what actually matters.

Final Thoughts: Who Is Vilon Actually For?

Vilon is not a recovery or body composition compound. It is a narrow, mechanistically specific research tool aimed at the progressive silencing of immune gene expression through chromatin compaction. The researchers who have studied it most extensively are interested in long-term immune trajectory, not acute performance metrics.

Within the Khavinson framework, Vilon occupies a non-redundant position. For someone who has already addressed the pineal and tissue-repair axes, the thymus-targeted epigenetic work that Vilon represents is a logical area to investigate further, under qualified clinical oversight.

VENDOR DIRECTORY

Research-grade Vilon is available through vendors listed in the Project Biohacking vendor directory. Each listing is reviewed for COA documentation, third-party testing standards, and sourcing transparency.

Vilon Bioregulator FAQs

REFERENCES

1. Khavinson VKh, Linkova NS, Polyakova VO, Kvetnoy IM. Peptide KE regulation of gene expression and chromatin state in old human fibroblasts. Bull Exp Biol Med. 2011;152(1):114-117.

2. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide KE activates chromatin in old human lymphocytes. Neuro Endocrinol Lett. 2003;24(3-4):177-182.

3. Lezhava T, Monaselidze J, Jokhadze T, et al. Activation of nucleolar organizer regions (NOR) and chromatin in aged human lymphocytes by KE peptide. Tsitologiia. 2005;47(8):688-693.

4. Linkova NS, Diatlova AS, Trofimova SV, et al. Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium. Lung. 2020;198(2):403-410.

5. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240.

6. Khavinson VKh, Linkova NS, Kvetnoy IM, et al. KE peptide: Effects on expression of Ki-67 and MMP-9 in human fibroblast culture. Bull Exp Biol Med. 2013;154(5):663-666.

7. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505.

8. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202.